| Literature DB >> 28372273 |
Abstract
The regulation for the use of stem cells has evolved during the past decade with the aim of ensuring a high standard of quality and safety for human derived products throughout Europe to comply with the provision of the Lisbon treaty. To this end, new regulations have been issued and the regulatory status of stem cells has been revised. Indeed, stem cells used for therapeutic purposes can now be classified as a cell preparation, or as advanced therapy medicinal products depending on the clinical indication and on the procedure of cell preparation. Furthermore, exemptions to the European regulation are applicable for stem cells prepared and used within the hospital. The aim of this review is to give the non-specialized reader a broad overview of this particular regulatory landscape.Entities:
Keywords: Advanced Therapy Medicinal Products (ATMP); European regulation; somatic cell therapy; tissue engineering
Mesh:
Year: 2017 PMID: 28372273 DOI: 10.3233/BME-171619
Source DB: PubMed Journal: Biomed Mater Eng ISSN: 0959-2989 Impact factor: 1.300